Pharma company Boehringer Ingelheim and Click Therapeutics announced an expanded partnership to develop and commercialize another prescription digital therapeutic for patients with schizophrenia.
The deal will net Click up to $460 million, plus tiered royalties. It builds on an earlier collaboration announced in 2020 that developed CT-155, an initial therapeutic for schizophrenia.
The companies...
Novartis has published results from a clinical trial of Pear Therapeutics' new digital therapeutic for schizophrenia, and the results don't paint a rosy picture.
The single-blinded 112-person trial found no difference between the Pear app and a placebo app in any outcome measure, including the primary outcome measure of reducing schizophrenia symptoms. However, the trial did further establish the...
Facebook activity can be used to identify people with mood disorders and schizophrenia spectrum disorders more than a year prior to their first psychiatric hospitalization, according to research published in npj Schizophrenia.
Although these findings are not meant to substitute for clinical psychiatric assessments, the results suggest that social media data can be used in addition to clinical...
International pharma Boehringer Ingelheim and prescription digital therapeutics company Click Therapeutics have inked a $500 million-plus deal to jointly develop and commercialize a digital treatment for patients with schizophrenia.
The treatment, referred to as CT-155, will be a mobile app built on Click's proprietary tech platform, the companies said.
Employing cognitive and neurobehavioral...
Pear Therapeutics is rolling out its new digital therapeutic aimed at treating schizophrenia for limited distribution, after the FDA loosened up its regulations for digital psychiatric disorders devices during the coronavirus crisis.
The new tool, called Pear-004, uses multimodal neurobehavioral interventions combined with antipsychotic medications. Patients with schizophrenia can use the tool...
Pear Therapeutics has inked a deal with pharma company Novartis to work together on the development of two digital therapeutics for multiple sclerosis and schizophrenia. It’s the first time a pharma company has made a development deal with a digital therapeutic, according to Pear.
“We have been in discussions for many months now with the [Novartis Institutes for BioMedical Research] group at...
A small study recently published in Translational Psychiatry showed that people living with schizophrenia could use a video game paired with an MRI scanner to curb verbal hallucinations.
Specifically, researchers at King’s College London’s Institute of Psychiatry, Psychology, and Neuroscience found that after the training people with schizophrenia were able to better control the verbal region in...
Pear Therapeutics, a Boston and San Francisco-based developer of digital strategies to address a broad range of mental health conditions, has released results of a study showing promising engagement with its program Thrive, which uses a smartphone app along with medication to treat patients with schizophrenia, schizoaffective disorder and bipolar disorder.
Thrive offers 24/7 patient monitoring...
Proteus Digital Health, the ingestible sensor company that raised $45 million in May -- the largest funding raise in digital health this year so far -- has published the results of a small clinical trial in a peer-reviewed journal. The study of 27 adults with bipolar disorder or schizophrenia found that the addition of an ingestible sensor to their regiment led to 67 percent of patients taking...
Proteus Biomedical's Raisin system
Intelligent medicine platform developer Proteus Biomedical has changed its name to Proteus Digital Health, to "better reflect" what the company does, Chief Product Officer David O'Reilly told MobiHealthNews in an email this week. Proteus also inked a deal with Japan-based Otsuka Pharmaceutical, which is known for its Abilify drug for schizophrenia and bipolar...
_1.jpg?itok=wDEAkDAi "A woman holding a smartphone looking out a window.")
